LARRY LIPSHULTZ to Prostate-Specific Antigen
This is a "connection" page, showing publications LARRY LIPSHULTZ has written about Prostate-Specific Antigen.
Connection Strength
0.665
-
Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy. Int J Impot Res. 2008 Nov-Dec; 20(6):561-5.
Score: 0.280
-
Testosterone replacement therapy in men on active surveillance for prostate cancer. J Sex Med. 2025 Apr 08; 22(3):432-438.
Score: 0.219
-
The role of testosterone replacement therapy following radical prostatectomy. Urol Clin North Am. 2007 Nov; 34(4):549-53, vi.
Score: 0.065
-
Testosterone Therapy after Radiation Therapy for Low, Intermediate and High Risk Prostate Cancer. J Urol. 2015 Nov; 194(5):1271-6.
Score: 0.028
-
Current state of practice regarding testosterone supplementation therapy in men with prostate cancer. Steroids. 2014 Nov; 89:27-32.
Score: 0.026
-
Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013 Aug; 190(2):639-44.
Score: 0.024
-
Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res. 2013 Jan; 25(1):24-8.
Score: 0.023